secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001213900-25-010711
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada acquires Sepranolone for €3M; Phase 2b-ready for Tourette syndrome
--------------------------------------------------------------------------

- Acquired Sepranolone (GAMSA neurosteroid) from Asarina Pharma AB for €3 million; €2.756M due within 10 business days.
- Phase 2a data: 28% reduction in tic severity (YGTSS, p=0.051); 69% greater quality-of-life improvement vs standard of care.
- Phase 2b-ready asset for Tourette syndrome and other compulsive disorders; no CNS off-target effects in Phase 2a.
- Relmada to host investor update on next development steps later in 2025.
- Deal includes full global ownership rights; Asarina retains pre-closing liabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025010711/0001213900-25-010711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025010711/ea0230164-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-010711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer